@article{8b6cb33b8e854b7082f08cc081fc06c9,
title = "From IgG fusion proteins to engineered-specific human regulatory T cells: A life of tolerance",
abstract = "Recent efforts have concentrated on approaches to expand and {"}specify{"} human regulatory T cells (Tregs) and to apply them to modulate adverse immune responses in autoimmunity and hemophilia. We have used retroviral transduction of specific T-cell receptor, single chain Fv, or antigen domains in Tregs to achieve this goal. Each of these approaches have advantages and disadvantages. Results with these engineered T cells and evolution of the research developments and paths that led to the development of specific regulatory approaches for tolerance are summarized.",
keywords = "B-cell receptor, Chimeric antigen receptor, Engineered T cells, Hemophilia A, Multiple sclerosis, Regulatory T cells, Single-chain variable fragment",
author = "Scott, {David W.}",
note = "Funding Information: The research summarized herein was supported by grants from the NIH (NIAID and NHLBI), Pfizer, and the NMSS. I thank Drs. Kate Pratt, Anja Schmidt, and Christoph K{\"o}nigs for specific receptors and recent members of the Scott lab (Patrick Adair, Maha Abdeladhim, Yongchan Kim, Kalpana Parvathaneni, Jeongheon Yoon, and Aihong Zhang) for their devotion and contributions to this research, and for a critical reading of this paper. Dr. J. R. Thistlethwaite, Jr., first pointed out the Sherlock Holmes quotes. This review is solely the responsibility of the speaker and does not necessarily represent the official views of the Department of Defense, the NIH, nor the US government. Publisher Copyright: {\textcopyright} 2017 Scott.",
year = "2017",
month = nov,
day = "13",
doi = "10.3389/fimmu.2017.01576",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
number = "NOV",
}